Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesMedtronic Demonstrates Positive Results on First Pacemaker Designed for Use with MRI
Medtronic, 05/15/09
New data announced at Heart Rhythm 2009, the annual congress of the Heart Rhythm Society, demonstrate that patients implanted with the investigational EnRhythm MRI SureScan pacing system experienced no complications related to the use of magnetic resonance imaging. Sponsored by Medtronic, Inc., the study confirms that the pacing system can help cardiac device patients benefit from the use of MRI, a critical imaging technique commonly used in disease diagnosis. Currently, due to safety considerations, there are no implantable pacemakers or defibrillators approved for use with MRI in the United States. Commercially released in Europe last fall, the EnRhythm MRI SureScan system is the world's first and only pacing system designed and approved for use with MRI.
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Interferon-gamma (INF-gamma) release test can detect cutaneous adverse effects to statins
International Journal of Dermatology, 12/03/09
Valsartan and aliskiren (Valturna): Combination of an angiotensin receptor blocker with direct renin inhibitor approved for the treatment of hypertension
Formulary , 12/02/09
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
Vascular Health and Risk Management, 12/01/09
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
Shire, 12/03/09
Allos Therapeutics Announces Issuance of U.S. Patent for FOLOTYN
Allos Therapeutics, 12/01/09
Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Archives of Neurology, 11/23/09
Sponsor
Article Search
Sponsor